Month: May 2017

Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay May 12, 2017 Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and Drug Administration (FDA). The clinical studies are designed to validate the performance and evaluate the implementation of the OncAlert

Clinical Lab Trends for 2017 May 12, 2017 Oral cancer – including cancers of the mouth and throat – is an area that is attracting new attention from the diagnostic community – this time with the help of dentists. New, promising technologies are making it easier for dental and medical professionals to detect oral cancer

Oral Cancer Tests May 12, 2017 The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker,

Number To Know…1,000 May 12, 2017 Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test. Source: Medtech Insight Back to News

The Word of Mouth on Oral Cancer May 3, 2017 Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population. While all adults should be screened for oral cancer annually, those who smoke or use smokeless tobacco, and/or consume alcohol